Skip to main content

If You Have “One Shot on Goal” in EGFR-Mutated NSCLC, Which Approach Is Best?

*April 2024*

“The rapidly evolving first-line treatment landscape for patients with metastatic EGFR mutant non-small cell lung cancer (NSCLC)” remains a “hot topic,” according to Eric K. Singhi, MD, assistant professor at the University of Texas MD Anderson Cancer Center. He and fellow “Leading Thoughts: Lung Cancer” panelists Maya Khalil, MD, thoracic oncologist at the University of Alabama at Birmingham, and Sandip Patel, MD, professor of medicine at the University of California San Diego, discuss how results from the FLAURA2 trial and the MARIPOSA trial have expanded options but also introduced important questions. Dr. Patel explains how he weighs options in cases where he believes he may have only “one shot on goal,” while Dr. Khalil asks whether using osimertinib and chemotherapy as a frontline approach is “really helping more patients or is it just shifting toxicities to an earlier setting?” Although Dr. Singhi notes that “it’s always exciting to offer more promise, more hope, to these patients,” he acknowledges that a lack of key data poses a challenge for oncologists. Watch video here.